证券代码：600208 证券简称：衢州发展 公告编号：2026-004 衢州信安发展股份有限公司 2025 年度业绩预减公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 业绩预告的具体适用情形：实现盈利，且净利润与上年同期相比 下降 50%以上。 预计2025年度实现归属于母公司所有者的净利润约20,000万元， 与上年同期相比，将减少 81,574 万元，同比减少 80.31%。 预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益 的净利润约 54,000 万元，与上年同期（法定披露数据）相比，预计 减少 121,190 万元，同比减少 69.18%。 二、上年同期经营业绩和财务状况 一、本期业绩预告情况 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 经财务部门初步测算，预计 2025 年年度实现归属于母公司所有 者的净利润约 20,000 万元，与上年同期（法定披露数据）相比，预 计减少 81,574 万元，同比减少 80.31%。 ...

Financial Performance - The company expects a net loss of 150 million yuan for the fiscal year 2025, compared to a net loss of 190.98 million yuan in the same period last year[3] - The loss attributable to shareholders is projected to be 168 million yuan after deducting non-recurring gains and losses, an increase from 203.85 million yuan in the previous year[3] - Basic earnings per share are expected to be a loss of 0.11 yuan per share, compared to a loss of 0.14 yuan per share in the prior year[3] Factors Affecting Loss - The increase in net loss is attributed to foreign exchange losses due to currency fluctuations, which negatively impacted net profit[5] - The company has made provisions for potential additional losses related to arbitration concerning its natural gas power generation project in Mexico[5] - Impairment provisions have been made for long-term equity investments and other assets due to identified risks[5] Financial Reporting - The financial data presented is preliminary and will be detailed in the company's annual report for 2025[7] - The company has communicated with its accounting firm regarding the earnings forecast, with no significant discrepancies reported[4] - The earnings forecast period is from January 1, 2025, to December 31, 2025[3] - Investors are advised to exercise caution and consider investment risks based on the preliminary nature of the financial data[7]

2、业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形 （1）以区间数进行业绩预告的 | 项 | 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 东的净利润 | | 盈利：28,400 万元–37,700 | | 万元 | 盈利：64,674 | 万元 | | | | 比上年同期下降：56.09%–41.71% | | | | | | 扣除非经常性损益 后的净利润 | | 盈利：36,200 | 万元–46,000 | 万元 | 盈利：25,354 | 万元 | | | | 比上年同期增长：42.78%–81.43% | | | | | | 基本每股收益 | | 盈利：0.1936 元/股 | 元/股–0.2569 | | 盈利：0.4408 | 元/股 | 二、与会计师事务所沟通情况 证券代码：002399 证券简称：海普瑞 公告编号：2026-001 深圳市海普瑞药业集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性 ...

证券代码：688075 证券简称：安旭生物 公告编号：2026-003 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 1、经财务部门初步测算，杭州安旭生物科技股份有限公司（以下简称"公司"） 预计 2025 年年度实现归属于母公司所有者的净利润 7,100.00 万元到 8,500.00 万元， 与上年同期（法定披露数据）相比，将减少 10,729.53 万元到 12,129.53 万元，同 比减少 55.80%到 63.08%。 2、预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净利润 1,300 万元到 1,560 万元，与上年同期（法定披露数据）相比，将减少 2,229.79 万 元到 2,489.79 万元，同比减少 58.84%到 65.70%。 （三）本次业绩预告为本公司初步测算，未经注册会计师年度审计。 杭州安旭生物科技股份有限公司 三、 ...

Financial Performance Forecast - The company expects a net profit of -10,300万元 for the year 2025, representing a decline of 1,015.05% compared to the previous year's profit of -6,500万元[4] - The net profit after deducting non-recurring gains and losses is projected to be -9,120万元, a decrease of 614.56% from -5,320万元 in the same period last year[4] - Basic earnings per share are expected to be -0.4790元, down from -0.3023元 in the previous year[4] Factors Affecting Performance - The decline in performance is attributed to a significant drop in titanium dioxide product prices due to weak downstream market demand, coupled with a year-on-year increase in raw material sulfuric acid prices[6] Communication and Disclosure - The company has communicated with the accounting firm regarding the preliminary financial data, and there are no discrepancies in the earnings forecast[5] - The company emphasizes that the earnings forecast is based on preliminary estimates and the actual financial data will be disclosed in the formal 2025 annual report[7] - Investors are advised to make cautious decisions and be aware of investment risks due to the preliminary nature of the earnings forecast[7]

证券代码：600078 证券简称：澄星股份 公告编号：临2026-002 江苏澄星磷化工股份有限公司 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●江苏澄星磷化工股份有限公司（以下简称"公司"）本期业绩预告的具体适 用情形：净利润实现扭亏为盈； （一）利润总额：-15,625.43万元。归属于母公司所有者的净利润：-19,889.64 万元。归属于母公司所有者的扣除非经常性损益的净利润：-20,762.64万元。 ●预计2025年年度实现归属于母公司所有者的净利润为650.00万元至970.00 万元，与上年同期相比，将实现扭亏为盈； ●预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润 为-5,200.00万元至-2,800.00万元。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经公司财务部门初步测算，预计2025年年度实现归属于母公司所有者的 净利润为650.00万元至970.00万元，与上年同 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 证券代码：688013 证券简称：天臣医疗 公告编号：2026-005 天臣国际医疗科技股份有限公司 2025 年年度业绩预告 （二）业绩预告情况 （1）经天臣国际医疗科技股份有限公司（以下简称"公司"）财务部门初步 测算，预计2025年年度实现归属于母公司所有者的净利润与上年同期（法定披露 数据）相比，将增加3,100.00万元到3,700.00万元，同比增加59.74%到71.30%。 （2）预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利 润与上年同期（法定披露数据）相比，将增加2,700.00万元到3,100.00万元，同比 增加57.77%到66.32%。 （三） 本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 （一）利润总额：5,483.14万元。归属于母公司所有者的净利润：5,189.48 万元。归属于母公司所有者的扣除非经常性损益的净利润： ...

Financial Projections - The estimated net profit for 2025 is projected to be a loss of RMB 140 million to RMB 160 million, representing a decrease of 37.91% to 45.67% compared to the loss of RMB 257.70 million in the previous year[3]. - The net profit after deducting non-recurring gains and losses is expected to be a loss of RMB 128 million to RMB 148 million, a reduction of 42.69% to 50.43% from the previous year's loss of RMB 258.24 million[3]. - The company anticipates a non-recurring loss of approximately RMB -12 million for 2025, primarily due to fair value changes[7]. Business Performance - The company's pesticide business revenue has shown steady growth, but overall gross margin remains low due to intensified market competition and some innovative products still ramping up production capacity[5]. - The pharmaceutical business is in collaboration with key clients, but the short duration of these partnerships has not yet positively impacted the company's performance[6]. - The subsidiary engaged in biomass waste resource processing is facing challenges due to industry cycles and market competition, leading to a contraction in project scale and expected impairment of receivables[6]. Strategic Investments - The company is investing in innovative pharmaceutical and pesticide projects, which may pressure cash flow and profits in the short term but aims to enhance long-term competitiveness[6]. - The company will conduct impairment testing on goodwill assets, expecting to recognize goodwill impairment[6].

Financial Projections - The estimated net profit for 2025 is projected to be between -200 million and -160 million CNY, compared to -140 million CNY in the same period last year[4]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between -210 million and -150 million CNY, compared to -512 million CNY in the same period last year[4]. - Estimated operating revenue for 2025 is projected to be between 340 million and 380 million CNY, compared to 335.7 million CNY in the same period last year[4]. - The estimated basic earnings per share is projected to be -0.1001 CNY, compared to -0.0701 CNY in the same period last year[4]. Loss Factors - The main reasons for the loss include industry adjustments and liquidity issues, impacting net profit by approximately -200 million to -160 million CNY due to provisions for receivables and interest expenses[6]. - The fair value decline of financial assets and penalties from debt defaults is expected to impact net profit by approximately -70 million to -40 million CNY, classified as non-recurring losses[6]. Non-Recurring Gains - Gains from the disposal of long-term equity investments and recovery of bad debts are expected to positively impact net profit by approximately 60 million to 70 million CNY, classified as non-recurring gains[6]. Financial Reporting - The financial data is preliminary and will be finalized after assessment and audit, with detailed disclosures in the 2025 annual report[7]. - The company has communicated with its accounting firm regarding the earnings forecast, with no significant discrepancies noted[5]. - Investors are advised to exercise caution and consider investment risks based on the preliminary nature of the earnings forecast[7].

证券简称：国际实业 证券代码：000159 编号：2026-07 新疆国际实业股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日－2025年12月31日 2、业绩预告情况：☐ 亏损 ☑ 扭亏为盈 ☐ 同向上升 ☐ 同向下降 | 项 | 目 | 本报告期 | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | | 盈利：约 | 3,600 | 万元 | 亏损：43,878.20 | 万元 | | | | 比上年同期增长：约 | | 108.20% | | | | 扣除非经常性损 益后的净利润 | | 盈利：约 | 3,670 | 万元 | 盈利：5,389.41 | 万元 | | | | 比上年同期下降：约 | | 31.90% | | | | 基本每股收益 | | 盈利：约 | 0.0749 | 元/股 | 亏损：0.9128 | 元/股 | 二、与会计师事务所沟通情况 本 ...